Patents by Inventor Yihan Wang

Yihan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11459334
    Abstract: Provided in the present invention are a substituted pyrrolotriazine compound, a pharmaceutical composition thereof and a use thereof, the pyrrolotriazine compound being a compound represented by formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate or solvent compound, crystalline form, stereoisomer or isotope variant thereof. The compound and composition of the present invention may be used in the treatment of conditions associated with KIT and/or PDGFR?.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 4, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Patent number: 11453672
    Abstract: Provided are pharmaceutical compositions comprising substituted pyrazolo[1,5-a]pyrimidine compounds and the use thereof. The compositions may comprise the substituted pyrazolo[1,5-a]pyrimidine compound or a pharmaceutically acceptable salt, prodrug, hydrate or solvate, polymorph, stereoisomer or isotopic variant thereof, and can be used for treating diseases treatable with Trk kinase inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: September 27, 2022
    Assignee: SHENZHEN TARGETRX, INC.
    Inventors: Yihan Wang, Jiuyang Zhao
  • Patent number: 11447512
    Abstract: An antiviral nucleoside reverse transcriptase inhibitor compound as shown in formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form or an isotopic derivative of the compound. A preparation method therefor, a pharmaceutical composition thereof, and a use thereof in the preparation of a drug for treating and/or preventing viral infectious diseases, such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: September 20, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao
  • Publication number: 20220251046
    Abstract: The present invention provides substituted pyrazole compounds, compositions containing same, and use thereof. The substituted pyrazole compounds comprise a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate, or solvate thereof. The compound represented by formula (I) can serve as a tissue selective androgen receptor modulator (SARM), particularly serving as a drug for treating prostate cancer and other AR-dependent conditions and diseases in which AR antagonism is desired.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 11, 2022
    Inventors: Yihan WANG, Xingye REN
  • Patent number: 11399840
    Abstract: In some examples, an embolization device includes multiple sections with three-dimensional non-helical structures when deployed at a vascular site. The multiple sections include a first section and one or more second sections that are smaller than the first section. The first section may have a deployed structure configured to anchor the device at a vascular site (e.g., a blood vessel) of a patient while each of the one or more second sections may be formed from loops that configured to pack and obstruct the vascular site. In some cases, the embolization device also includes a third section having a deployed configuration with multiple helical windings or loops is configured to anchor the embolization device at the vascular site.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 2, 2022
    Assignee: COVIDIEN LP
    Inventors: Yihan Wang, Victoria Schuman, Zhimin Fang, Yapeng Xu, Haitao Cao, Zhipeng Chen, Xiaojing Guo, Shichang Wen
  • Publication number: 20220237429
    Abstract: A system for providing a persona-driven and artificially-intelligent avatar is disclosed. The avatar may be utilized to represent an artificially-intelligent virtual assistant that may perform actions on behalf of a user, such as actions related to personal shopping for the user. Notably, the avatar may influence artificial intelligence algorithms supporting the functionality of the virtual assistant via quantifiable traits of a persona of the avatar. In particular, the quantifiable traits of the persona of the avatar may be utilized to range bound the controlling parameters of the algorithms such that the virtual assistant represented by the avatar performs actions that conform to the ranged-bounded controlling parameters. Metrics corresponding to the performance of the virtual assistant may be tracked, and the system may modify parameters of the virtual assistant based on the metrics so as to adjust future actions performed by the virtual assistant for the user.
    Type: Application
    Filed: April 12, 2022
    Publication date: July 28, 2022
    Applicant: Graphen, Inc.
    Inventors: Ching-Yung Lin, Danny Lo-Tien Yeh, Yizhou Shen, Yihan Wang, Yuting An, Xinwei Li
  • Patent number: 11389463
    Abstract: The present invention relates to a compound of a novel antiviral nucleoside reverse transcriptase inhibitor, a pharmaceutical composition containing the compound, and preparation and application of the compound. Specifically, disclosed in the present invention are a fused pyrimidine compound as represented by formula (I) and a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate, crystal form, prodrug or isotopic derivative of the compound. The compound of the present invention can be used for treatment and/or prevention of infectious diseases caused by viruses, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV).
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: July 19, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao
  • Patent number: 11384069
    Abstract: Provided in the present invention are a pharmaceutical composition of a substituted diphenylaminopyrimidine compound and a use thereof, wherein the compound is the compound as shown in formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate or solvate, crystal form, N-oxide and various diastereomers thereof. The compound of the present invention can be used for treating diseases that can be treated with the JAK2 kinase inhibitor.
    Type: Grant
    Filed: September 30, 2018
    Date of Patent: July 12, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Patent number: 11358973
    Abstract: A di(hetero)aryl macrocyclic compound having an inhibitory effect on protein kinase activity, preparation and the use thereof. Specifically, disclosed are a di(hetero)aryl macrocyclic compound represented by formula (I), or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, a solvate, a hydrate, a polymorph, a prodrug or an active metabolite thereof, a pharmaceutical composition comprising said compound and the derivative thereof, and methods of using the same, including methods of treating cancers, pain, neurological diseases, autoimmune diseases and inflammation.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: June 14, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • Patent number: 11345703
    Abstract: Provided are a pharmaceutical composition of a substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound and the use thereof. The pyrazolo[1,5-a]pyrimidine macrocyclic compound is a compound as shown in formula (Aa), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate, a crystal form, a stereoisomer or an isotopic variant thereof. The compound of the present invention is an inhibitor of the Trk kinase, and can be used for treating pain, cancers, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: May 31, 2022
    Assignee: SHENZHEN TARGETRX, INC.
    Inventors: Yihan Wang, Jiuyang Zhao
  • Patent number: 11319317
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 3, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • Patent number: 11301746
    Abstract: A system for providing a persona-driven and artificially-intelligent avatar is disclosed. The avatar may be utilized to represent an artificially-intelligent virtual assistant that may perform actions on behalf of a user, such as actions related to an investment strategy for the user. Notably, the avatar may influence artificial intelligence algorithms supporting the functionality of the virtual assistant via quantifiable traits of a persona of the avatar. In particular, the quantifiable traits of the persona of the avatar may be utilized to range bound the controlling parameters of the algorithms such that the virtual assistant represented by the avatar performs actions that conform to the ranged-bounded controlling parameters. Metrics corresponding to the performance of the virtual assistant may be tracked, and the system may modify parameters of the virtual assistant based on the metrics so as to adjust future actions performed by the virtual assistant for the user.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: April 12, 2022
    Assignee: Graphen, Inc.
    Inventors: Ching-Yung Lin, Danny Lo-Tien Yeh, Yizhou Shen, Yihan Wang, Yuting An, Xinwei Li
  • Publication number: 20220098204
    Abstract: Provided are a substituted fused aromatic ring derivative, a composition containing the compound, and a use thereof. The substituted fused aromatic ring derivative is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound and the composition can be used to treat various protein tyrosine kinase-mediated diseases or disorders.
    Type: Application
    Filed: February 13, 2020
    Publication date: March 31, 2022
    Applicant: Shenzhen TargetRX, Inc.
    Inventors: Yihan Wang, Qingfeng Xing, Yixin Ai
  • Publication number: 20220081440
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: October 12, 2021
    Publication date: March 17, 2022
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Patent number: 11267810
    Abstract: Provided are an aminopyrimidine compound as shown in formula (I), a polymorph, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotopic variant, a hydrate or a solvate thereof, and a pharmaceutical composition containing the same and the use thereof. The aminopyrimidine compound and the composition containing the same have excellent inhibition to protein kinases, and at the same time have better pharmacokinetic parameter characteristics, and can improve the drug concentration of the compound in animals, and thereby improve the efficacy and safety of the drug.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 8, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Patent number: 11267806
    Abstract: The present invention relates to an indazole compound for use in inhibiting kinase activity, and relates to a preparation and use thereof. Specifically disclosed in the present invention is an indazole compound represented by formula (I), or a crystal form, a prodrug, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a solvate or a hydrate thereof, or a pharmaceutical composition thereof. The compound of the present invention and the composition containing the compound have an excellent inhibitory effect on kinase proteins, and have better pharmacokinetic parameter characteristics, may increase the drug concentration of the compound in an animal, and improve the efficacy and safety of the drug.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: March 8, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Publication number: 20220064144
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
    Type: Application
    Filed: August 12, 2021
    Publication date: March 3, 2022
    Inventors: Nicholas E. BENCIVENGA, David C. DALGARNO, Joseph M. GOZGIT, Wei-Sheng HUANG, Anna KOHLMANN, Feng LI, Jiwei QI, William C. SHAKESPEARE, Ranny M. THOMAS, Yihan WANG, Yun ZHANG, Xiaotian ZHU
  • Patent number: 11254696
    Abstract: Disclosed are a dianilino pyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition containing these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: February 22, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Publication number: 20220048891
    Abstract: The present invention relates to an aminopyrimidine compound having an inhibitory effect on the activity of protein kinase as well as the preparation and use thereof. Specifically, disclosed by the present invention is an aminopyrimidine compound represented by formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate or hydrate thereof, as well as a pharmaceutical composition comprising said compound and a use method therefor. The method comprises a method for treating cell proliferative diseases and conditions such as cancer and immune diseases.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 17, 2022
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Patent number: D944370
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: February 22, 2022
    Inventors: Chengye Huang, Huanlong Wu, Linjun Yu, Weirui Liu, Zhaoyang Wu, Jiapeng Wang, Donglin Song, Haiping Tian, Yihan Wang